| Date | Source | Headline |
|---|---|---|
| 8th Dec 2025 1:00 pm | MFN | BioInvent Presents Impressive Response Data from Ongoing Phase 2a Trial of Triple Combination BI-1206, Rituximab, and Calquence in r/r NHL at ASH 2025 |
| 7th Dec 2025 1:00 pm | MFN | BioInvent Presents Promising Early Phase 2a BI-1808 Monotherapy Data in CTCL at ASH 2025 |